All Articles

Participation in certified educational activities resulted in significant improvements in knowledge, competence, and confidence regarding the use of CDK4/6 inhibitor therapies in the management of patients with advanced HR-positive breast cancer.

The combination of exemestane and entinostat did not show survival benefit in patients with aromatase inhibitor–resistant, HR-positive, HER2-negative advanced breast cancer.

Subgroup analysis of the phase 3b CompLEEment-1 clinical trial supports the use of ribociclib combined with letrozole in HR-positive, HER2-negative advanced breast cancer male patients based on demonstrated efficacy and safety.

In a predominantly black, low-income population, women with diabetes and incident localized breast cancer had decreased overall survival when compared with those without diabetes.

Subgroup analysis of the phase 3b CompLEEment-1 clinical trial reinforces the efficacy and safety of ribociclib plus letrozole in premenopausal patients with HR-positive, HER2-negative advanced breast cancer.

An alternative schedule of palbociclib reduced grade ≥3 neutropenia and showed efficacy data comparable with previous reports.

Findings from this study show that based on the adjusted adherence rate of the combination therapy of exemestane and everolimus, a low-rate adherence was observed.

Consistent with previous phase 3 studies with ribociclib and letrozole, few patients with HR-positive, HER2-negative advanced breast cancer and central nervous system metastases discontinued treatment due to side effects.